These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34368919)

  • 1. Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression.
    Zhdanava M; Karkare S; Pilon D; Joshi K; Rossi C; Morrison L; Sheehan J; Lefebvre P; Lopena O; Citrome L
    Adv Ther; 2021 Sep; 38(9):4900-4916. PubMed ID: 34368919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
    Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
    JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant Depression.
    Benson C; Szukis H; Sheehan JJ; Alphs L; Yuce H
    Am J Geriatr Psychiatry; 2020 Mar; 28(3):350-362. PubMed ID: 31735488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of treatment-resistant depression among veterans in the United States.
    Szukis H; Joshi K; Huang A; Amos TB; Wang L; Benson CJ
    Curr Med Res Opin; 2021 Aug; 37(8):1393-1401. PubMed ID: 33879005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States.
    Karkare S; Zhdanava M; Pilon D; Nash AI; Morrison L; Shah A; Lefebvre P; Joshi K
    Clin Ther; 2022 Nov; 44(11):1432-1448. PubMed ID: 36207167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of treatment resistant depression among major depressive disorder patients in Israel.
    Sharman Moser S; Chodick G; Gelerstein S; Barit Ben David N; Shalev V; Stein-Reisner O
    BMC Psychiatry; 2022 Aug; 22(1):541. PubMed ID: 35948895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression.
    Wu B; Cai Q; Sheehan JJ; Benson C; Connolly N; Alphs L
    PLoS One; 2019; 14(8):e0220763. PubMed ID: 31393922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.
    Denee T; Kerr C; Ming T; Wood R; Tritton T; Middleton-Dalby C; Massey O; Desai M
    J Psychiatr Res; 2021 Jul; 139():172-178. PubMed ID: 34077893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of treatment-resistant depression: A retrospective observational study.
    Pérez-Sola V; Roca M; Alonso J; Gabilondo A; Hernando T; Sicras-Mainar A; Sicras-Navarro A; Herrera B; Vieta E
    J Affect Disord; 2021 Dec; 295():578-586. PubMed ID: 34509073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health records.
    Adekkanattu P; Olfson M; Susser LC; Patra B; Vekaria V; Coombes BJ; Lepow L; Fennessy B; Charney A; Ryu E; Miller KD; Pan L; Yangchen T; Talati A; Wickramaratne P; Weissman M; Mann J; Biernacka JM; Pathak J
    J Affect Disord; 2023 Mar; 324():102-113. PubMed ID: 36529406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Descriptive analysis of the economic burden of treatment resistance in a major depressive episode.
    Cai Q; Sheehan JJ; Wu B; Alphs L; Connolly N; Benson C
    Curr Med Res Opin; 2020 Feb; 36(2):329-335. PubMed ID: 31540559
    [No Abstract]   [Full Text] [Related]  

  • 17. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
    Wu Z; Chen J; Yuan C; Hong W; Peng D; Zhang C; Cao L; Fang Y
    J Affect Disord; 2013 Sep; 150(3):834-9. PubMed ID: 23570952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.
    Olfson M; Amos TB; Benson C; McRae J; Marcus SC
    J Manag Care Spec Pharm; 2018 Mar; 24(3):226-236. PubMed ID: 29485948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.
    Amos TB; Tandon N; Lefebvre P; Pilon D; Kamstra RL; Pivneva I; Greenberg PE
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polygenic risk scores of lithium response and treatment resistance in major depressive disorder.
    Xiong Y; Karlsson R; Song J; Kowalec K; Rück C; Sigström R; Jonsson L; Clements CC; Andersson E; Boberg J; Lewis CM; Sullivan PF; Landén M; Lu Y
    Transl Psychiatry; 2023 Sep; 13(1):301. PubMed ID: 37770441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.